Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.53 |
| ▸ | AKT2 | P31751 | 8/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391814 | 0.91 | AKT1 (0.55) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL20544959 | 0.90 | AKT1 (0.57) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL392121 | 0.82 | AKT1 (0.71) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL3650884 | 0.81 | AKT1 (0.52) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL391354 | 0.81 | AKT1 (0.51) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL392234 | 0.81 | AKT1 (0.74) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL390668 | 0.81 | AKT1 (0.73) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL3655529 | 0.80 | AKT1 (0.57) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL3659051 | 0.80 | AKT1 (0.51) | AKT1ROCK2AKT2AKT3KCNH2 | |
| SCHEMBL3655526 | 0.80 | AKT1 (0.51) | AKT1ROCK2AKT2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654855-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
| US-10059714-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-20170057969-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2017-03-02 | — | — | US | disclosed |
| US-9492453-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2016-11-15 | — | — | US | disclosed |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2015-07-02 | — | — | US | disclosed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| EP-2201012-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-10654855-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-10059714-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885ROCK2 85/4885AKT2 6/4885 |
| US-20170057969-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885ROCK2 85/4885AKT2 6/4885 |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885ROCK2 85/4885AKT2 6/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | AKT1 4/4885ROCK2 85/4885AKT2 6/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885ROCK2 60/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.